Now that the U.S. government has negotiated prices for some Medicare drugs that will take effect in 2026, Wall Street analysts are betting on a 2027 list that will include Novo Nordisk’s (NVO) diabetes blockbuster Ozempic and have only a limited impact on major pharmaceutical companies. Other possible candidates for 2027 include Pfizer’s (PFE) cancer […]